Natus Medical Incorporated (BABY) EPS Estimated At $0.06

Investors sentiment increased to 1.16 in Q4 2018. Its up 0.16, from 1 in 2018Q3. It improved, as 14 investors sold Natus Medical Incorporated shares while 49 reduced holdings. 22 funds opened positions while 51 raised stakes. 30.90 million shares or 8.21% more from 28.55 million shares in 2018Q3 were reported.
Cornerstone Advsrs Inc owns 15 shares. Price T Rowe Assoc Md accumulated 356,641 shares or 0% of the stock. Texas Permanent School Fund has 0.01% invested in Natus Medical Incorporated (NASDAQ:BABY) for 22,106 shares. First Tru Advisors Lp owns 41,985 shares or 0% of their US portfolio. South Dakota Inv Council owns 4,200 shares for 0% of their portfolio. Ubs Asset Management Americas Incorporated has invested 0% of its portfolio in Natus Medical Incorporated (NASDAQ:BABY). Fmr Limited Liability Com has 0% invested in Natus Medical Incorporated (NASDAQ:BABY). Bessemer Gru invested 0% of its portfolio in Natus Medical Incorporated (NASDAQ:BABY). Pinebridge Invs Ltd Partnership has 0.03% invested in Natus Medical Incorporated (NASDAQ:BABY). Employees Retirement Association Of Colorado owns 8,057 shares. 59,100 are held by Swiss National Bank. First Hawaiian Bancorp reported 804 shares. Moreover, Manufacturers Life Communication The has 0% invested in Natus Medical Incorporated (NASDAQ:BABY) for 20,004 shares. Citadel stated it has 13,332 shares. California Pub Employees Retirement invested 0% of its portfolio in Natus Medical Incorporated (NASDAQ:BABY).

Since October 26, 2018, it had 1 insider purchase, and 2 insider sales for $1.42 million activity. 30,000 shares were sold by LUDLUM KEN, worth $930,500. The insider Heine Lisa Wipperman bought $2,718.

Analysts expect Natus Medical Incorporated (NASDAQ:BABY) to report $0.06 EPS on April, 24.They anticipate $0.18 EPS change or 75.00 % from last quarter’s $0.24 EPS. BABY’s profit would be $2.01M giving it 105.75 P/E if the $0.06 EPS is correct. After having $0.43 EPS previously, Natus Medical Incorporated’s analysts see -86.05 % EPS growth. It closed at $25.38 lastly. It is down 8.36% since April 15, 2018 and is downtrending. It has underperformed by 12.73% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Natus Medical Incorporated provides newborn care and neurology healthcare services and products worldwide. The company has market cap of $850.73 million. It offers services and products used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. It currently has negative earnings. The company??s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories.

More notable recent Natus Medical Incorporated (NASDAQ:BABY) news were published by: Nasdaq.com which released: “MEDNAX Ties Up With Georgia Neonatology for Better Baby Care – Nasdaq” on April 02, 2019, also Nasdaq.com with their article: “Prince Harry and Meghan to keep baby plans private – Nasdaq” published on April 11, 2019, Businesswire.com published: “Six in Ten U.S. Adults are Concerned with Data Security at Fuel Pumps and Convenience Stores – Business Wire” on April 15, 2019. More interesting news about Natus Medical Incorporated (NASDAQ:BABY) were released by: Fool.com and their article: “The Walmart-New Age Beverages Tie-Up Should Surprise No One – The Motley Fool” published on April 15, 2019 as well as Nasdaq.com‘s news article titled: “Forget Brexit, there’s a new British royal baby on the way – Nasdaq” with publication date: March 28, 2019.

Natus Medical Incorporated (NASDAQ:BABY) Institutional Positions Chart